131 related articles for article (PubMed ID: 7705548)
1. Ulcerative colitis and Crohn's disease: factor XIII, inflammation and haemostasis.
Seitz R; Leugner F; Katschinski M; Immel A; Kraus M; Egbring R; Göke B
Digestion; 1994; 55(6):361-7. PubMed ID: 7705548
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease.
Van Bodegraven AA; Tuynman HA; Schoorl M; Kruishoop AM; Bartels PC
Scand J Gastroenterol; 1995 Jun; 30(6):580-5. PubMed ID: 7569767
[TBL] [Abstract][Full Text] [Related]
3. Differential behavior of coagulation factor XIII in patients with inflammatory bowel disease and in patients with giant cell arteritis.
Vrij AA; Rijken J; van Wersch JW; Stockbrügger RW
Haemostasis; 1999; 29(6):326-35. PubMed ID: 10844406
[TBL] [Abstract][Full Text] [Related]
4. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease.
Kjeldsen J; Lassen JF; Brandslund I; Schaffalitzky de Muckadell OB
Scand J Gastroenterol; 1998 Jun; 33(6):637-43. PubMed ID: 9669637
[TBL] [Abstract][Full Text] [Related]
5. Involvement of coagulation and hemostasis in inflammatory bowel diseases.
Stadnicki A
Curr Vasc Pharmacol; 2012 Sep; 10(5):659-69. PubMed ID: 22272910
[TBL] [Abstract][Full Text] [Related]
6. Significance of diminished factor XIII in Crohn's disease.
Chamouard P; Grunebaum L; Wiesel ML; Sibilia J; Coumaros G; Wittersheim C; Baumann R; Cazenave JP
Am J Gastroenterol; 1998 Apr; 93(4):610-4. PubMed ID: 9576457
[TBL] [Abstract][Full Text] [Related]
7. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.
Owczarek D; Undas A; Foley JH; Nesheim ME; Jabłonski K; Mach T
J Crohns Colitis; 2012 Feb; 6(1):13-20. PubMed ID: 22261523
[TBL] [Abstract][Full Text] [Related]
8. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut.
Pihusch R; Salat C; Göhring P; Hentrich M; Wegner H; Pihusch M; Hiller E; Kolb HJ; Ostermann H
Br J Haematol; 2002 May; 117(2):469-76. PubMed ID: 11972534
[TBL] [Abstract][Full Text] [Related]
9. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis.
Muszbek L; Bagoly Z; Bereczky Z; Katona E
Cardiovasc Hematol Agents Med Chem; 2008 Jul; 6(3):190-205. PubMed ID: 18673233
[TBL] [Abstract][Full Text] [Related]
10. [Coagulation system and inflammatory bowel disease: therapeutic and pathophysiologic implications].
Folwaczny C
Z Gastroenterol; 2002 Dec; 40(12):991-8. PubMed ID: 12518265
[TBL] [Abstract][Full Text] [Related]
11. Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes.
Soendergaard C; Kvist PH; Seidelin JB; Pelzer H; Nielsen OH
J Gastroenterol; 2016 Aug; 51(8):796-807. PubMed ID: 26660730
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
13. Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis.
Zimmermann-Nielsen E; Grønbaek H; Dahlerup JF; Baatrup G; Thorlacius-Ussing O
BMC Gastroenterol; 2005 Sep; 5():31. PubMed ID: 16179087
[TBL] [Abstract][Full Text] [Related]
14. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Folwaczny C; Wiebecke B; Loeschke K
Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
[TBL] [Abstract][Full Text] [Related]
15. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis.
Zezos P; Papaioannou G; Nikolaidis N; Patsiaoura K; Vassiliadis T; Mpoumponaris A; Giouleme O; Evgenidis N
Med Sci Monit; 2009 Nov; 15(11):CR563-72. PubMed ID: 19865055
[TBL] [Abstract][Full Text] [Related]
16. Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.
Saadah OI; Al-Harthi SE; Al-Mughales JA; Bin-Taleb YY; Baeshen RS
Int J Clin Exp Pathol; 2015; 8(12):16000-6. PubMed ID: 26884875
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
Eivindson M; Grønbaek H; Flyvbjerg A; Frystyk J; Zimmermann-Nielsen E; Dahlerup JF
Growth Horm IGF Res; 2007 Feb; 17(1):33-40. PubMed ID: 17126585
[TBL] [Abstract][Full Text] [Related]
18. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
[TBL] [Abstract][Full Text] [Related]
19. Factor XIII in chronic inflammatory bowel diseases.
Lorenz R; Olbert P; Born P
Semin Thromb Hemost; 1996; 22(5):451-5. PubMed ID: 8989830
[TBL] [Abstract][Full Text] [Related]
20. [A-subunit, b-subunit and a2b2-complex of coagulation factor XIII in inflammatory bowel disease].
Ohsone T; Kubota Y; Katsumata S; Horimukai F; Miyaoka M
Nihon Shokakibyo Gakkai Zasshi; 1988 Jun; 85(6):1317. PubMed ID: 3225950
[No Abstract] [Full Text] [Related]
[Next] [New Search]
